Huapu Scientific Completes RMB 100 Million Series A Financing to Build a World-Class Domestic Chromatography Brand with International Standards

Recently, Acchrom Tech (Beijing) Co., Ltd. (hereinafter referred to as “Acchrom Tech”) announced that it has completedSeries A Financing of Over 100 Million Yuan, marking the second financing round exceeding RMB 100 million completed by Acchrom Tech within the past year. This round was led by Honghui Fund, with Dinghui Investment participating as a co-investor, and existing shareholders Boyuan Capital and Chende Capital oversubscribing their pro-rata allocations.The financing is primarily used to expand chromatography sales channels and improve the service system.. Changhai Capital continues to serve as the exclusive financial advisor for the company's financing.

Acchrom Tech Completes Series A Financing

Liquid chromatographs and their consumables are highly significant products within the analytical instrumentation industry, finding extensive applications in pharmaceuticals, food safety, environmental protection, petrochemicals, and life sciences. The annual domestic market size in China has reached RMB 10 billion, maintaining robust double-digit growth. Currently, over 90% of the liquid chromatography market is dominated by imported products, presenting substantial opportunities for import substitution by domestic brands. As supply chain security and upstream industrial chains gain increasing attention from the government and investment institutions, many analytical instrumentation companies, including those specializing in chromatography, have emerged as promising bright spots amid the “capital winter.”

In response to this situation, Acchrom Tech has formulated a comprehensive and rational corporate development plan and strategy. The company aims to seize the opportunities of the times and actively pursue business growth, while maintaining a low-profile and pragmatic approach to enhance its sales and service capabilities, thereby achieving greater business breakthroughs.

Compared with other domestic manufacturers, Acchrom Tech holds advantages in the following aspects: (1) full independent development of chromatography instruments, consumables, and software; (2) one of the few companies in China to achieve mass production of liquid chromatographs and sales to mainstream mid-to-high-end customers.

In terms of equipment and consumables, Acchrom Tech has launched five self-developed models of high-performance liquid chromatographs (HPLC), ultra-high-performance liquid chromatographs (UHPLC), and liquid chromatography-mass spectrometry (LC-MS) systems, along with nearly 100 categories of liquid chromatography columns and sample pretreatment consumables, comprehensively meeting the R&D and production needs of customers in the pharmaceutical, food, environmental protection, petrochemical, and life sciences sectors.The company’s complete systems have undergone long-term evaluations by multiple well-known enterprises and institutions, with product performance and stability comparable to imported products.

The efficiency, reliability, and compliance of chromatographic analysis results largely depend on the software. Regulatory authorities both in China and abroad impose stringent requirements on chromatography software. Without high-performance, compliant chromatography software, domestic chromatography manufacturers will find it difficult to penetrate the customer base of mainstream pharmaceutical companies.In October 2022, Acchrom Tech releasedThe First Domestically Produced Chromatography Control Software with High Compliance, the software is independently developed by Acchrom Tech with full independent intellectual property rights, featuring end-to-end audit trails and advanced intelligent data analytics capabilities. Currently, multiple regulatory agencies and users have completed evaluations of this compliance-oriented version, confirming that the product fully meets domestic and international regulatory requirements. Compared to existing software on the market, it boasts a more advanced design philosophy, simpler operation, and richer functionality. In the future, the software is also planned to be extended to analytical instruments such as liquid chromatography-mass spectrometry (LC-MS) systems and gas chromatographs.

Acchrom Tech Product Matrix

Against the backdrop of a favorable industry environment, Mr. Wang Lichun, Founder and Chairman of Acchrom Tech, remains calm and clear-headed as an industry veteran. He stated, “The substitution of domestic products for imported ones is not an overnight process. To break down the barriers established by international brands, it is essential not only to build ‘hard power’ through high-quality, comprehensive product solutions but also to develop ‘soft power’ via a professional and systematic sales and service team. After achieving stable mass production, the more critical task is to rapidly expand market presence, enabling customers to see, use, and trust Acchrom Tech’s products.”

Guided by this philosophy, Acchrom Tech has established its management, technical, sales, and service teams in accordance with the standards of top-tier international corporations.Over the past year, senior industry experts—including executives, chief engineers, and heads of product, applications, and sales—from multiple leading international scientific instrument companies have joined Acchrom Tech.. Meanwhile, Acchrom Tech has also identified and cultivated a cohort of young talents in its technical, sales, and application departments based on international corporate standards. Currently, the company has established a comprehensive system encompassing marketing, sales, industry-specific solutions, technology, and after-sales service. In particular, regarding technical services, Acchrom Tech has built a highly competent application support team that engages deeply with customers to deliver solutions characterized by high professionalism and rapid responsiveness. To date, the company has developed over a thousand application solutions within its proprietary framework, covering fields such as chemical pharmaceuticals, traditional Chinese medicine, food, environmental monitoring, and chemical engineering.

Great buildings rise from the ground up. Currently, Acchrom Tech has alreadyMultiple National- and Provincial-Level Standard-Setting Bodies Conduct Evaluation and Upgrading of National Standards，This reflects not only the social responsibility of a leading domestic chromatography brand but also serves as the business foundation for ensuring broader commercial customers’ confidence in using Acchrom Tech’s products. Over the past year, Acchrom Tech completed the sales and installation of hundreds of instrument systems and related consumables for commercial clients, spanning enterprises and institutions across major sectors including pharmaceuticals, food, environmental protection, petrochemicals, and life sciences. With this achievement, Acchrom Tech has established both the “hard power” and “soft power” necessary to compete with international brands, positioning itself to fully embrace the golden age of accelerated localization of scientific instruments. Looking ahead, Acchrom Tech will continue to refine its product and service offerings while actively expanding into overseas markets and other horizontal business areas, providing customers with higher-quality analytical tool platforms.

Acchrom Tech Awarded Beijing “Specialized, Refined, Differential, and Innovative” Enterprise Certification

Wang Lichun, Founder of Acchrom TechStatement: We extend our sincere gratitude to both new and existing investment institutions for their recognition and support of Acchrom Tech. Over the past eight years since its establishment, the company has built a comprehensive product ecosystem encompassing chromatography, mass spectrometry, software, consumables, after-sales service, and applications, while attracting a large pool of elites from the analytical instrumentation industry. As a leading Chinese brand in liquid chromatography, Acchrom Tech shoulders the significant responsibility of driving the rise of domestically produced analytical instruments. Looking ahead, we will continue to hold ourselves to stringent international standards, consistently deliver value to a broader customer base, and ensure that analytical instruments made in China benefit the world!

Honghui Fund TeamStatement: Liquid chromatography is a key sector within scientific instrumentation. Acchrom Tech is a leading domestic liquid chromatography company in China, offering reliable chromatographic instruments, consumables, and network-based software. We look forward to the company’s continued rapid development and its provision of superior solutions for the life sciences and other industries.

Gao Jieliang, Senior Partner at CDH Innovation & Growth FundIt is evident that the localization of scientific instruments in China is supported by technological and industrial foundations, policy guidance, necessity, and robust market demand. Against the backdrop of China’s industrial upgrading, the domestication of scientific instruments has become an inevitable trend. We are optimistic about Acchrom Tech’s leading position and growth potential in the liquid chromatography sector, a major product category with a market size exceeding RMB 10 billion. The company has comprehensively laid out and deeply cultivated its capabilities across multiple segments, including chromatograph hardware, compliant software, stationary phases, and application methodologies. Acchrom Tech has assembled top-tier talent from both domestic and international chromatography industries and research institutions. Its products have been validated by leading Chinese pharmaceutical companies and regulatory agencies, and have also undergone performance testing by portfolio companies of CDH Investments. Looking ahead, Acchrom Tech is well-positioned to evolve into a multi-category platform for Chinese scientific instruments, building upon high-performance liquid chromatography (HPLC) as a cornerstone product in the field of scientific instrumentation. We will continue to provide long-term support for the company’s development.

Li Han, Vice President of Investment at Boyuan CapitalStatement: We express our gratitude to the new shareholders for their recognition and support of Acchrom Tech. Since the previous round of investment, the company has responded to the call issued by Party and state leaders to “win the critical battle for the domestication of scientific instruments and equipment,” achieving significant progress in team building, product development, and customer onboarding. Boyuan Capital will continue to support Acchrom Tech, making greater contributions to achieving self-reliance and strength in China’s scientific instrument sector.

Chende CapitalChende Capital remains bullish on Acchrom Tech’s work in the field of liquid chromatography. Under the leadership of Mr. Wang, the company has consistently maintained an excellent standard in product development—including software, hardware, and consumables—as well as in building and refining its sales and service support systems. With the continued support of both existing and new shareholders, we hope that Acchrom Tech will achieve further progress, break the long-standing monopoly held by foreign enterprises in this sector, and become a leading company in the analytical liquid chromatography industry.

Wang Keshu, Partner at Changhai CapitalIt stated: "We are delighted to continue our partnership with Acchrom Tech, and we sincerely appreciate the sustained recognition and support from both new and existing shareholders during this capital winter. The proactive yet pragmatic and rational approach of the Acchrom team has enabled Acchrom Tech to achieve significant milestones in less than a year, including stable mass production of its products and the establishment of partnerships with leading benchmark customers. Looking ahead, we will continue to drive product R&D and sales execution, striving to become a top-tier domestic brand."

Serving Chinese-style modernization, HLC Fund (HLC) is dedicated to discovering and realizing the enduring value of science and technology. Leveraging deep expertise in core fields such as chemistry, biology, and materials engineering, and grounded in independent in-depth research and systematic empowerment services, HLC Fund is committed to creating sustained positive impact on productivity transformation and the enhancement of public health through long-term value investments in the real economy and technological innovation. To date, HLC Fund has invested in over 100 high-quality companies, with 25 of them listed on stock exchanges both domestically and internationally. HLC Fund manages dual-currency funds in RMB and USD, and has established offices in Shanghai, Beijing, Shenzhen, Hong Kong, and other locations.

CDH VGC is a fund under CDH Investments focused on innovation and growth investments, combining the innovative vision of venture capital (VC) with the professional rigor of growth investing. It primarily covers four investment sectors: healthcare, ToC new consumption, ToB enterprise services, and hard-tech innovation. Since its inception, CDH VGC has adhered to CDH Investments’ core philosophy of partnering with strivers to create long-term value. Committed to addressing societal pain points, it helps companies improve efficiency and reduce costs through technological or business model innovation, having invested in nearly 90 leading innovative enterprises. CDH VGC firmly believes that allocating resources to outstanding innovative growth companies will inevitably drive progress in industries and society.

Boyuan Capital, established in 2017, is a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. Currently, Boyuan Capital manages two RMB funds and two USD funds, with total assets under management exceeding RMB 7 billion. More than just an investor, Boyuan Capital serves as a long-term partner to entrepreneurs. Since its inception, the firm has remained entrepreneur-centric, consistently supporting and actively empowering top-tier healthcare entrepreneurs, fostering an industry ecosystem, and cultivating the next generation of leading enterprises in China’s healthcare sector.

Chende Capital is an investment firm focused on innovative medical technologies and cutting-edge biotechnology sectors. It is managed and operated by a professional team with extensive experience in the healthcare industry, overseeing multiple RMB and USD-denominated funds.

Chende Capital adheres to the investment philosophy of “Focus, Excellence, and Reputation.” Leveraging its deep industrial resources in the healthcare sector and years of in-depth research and cultivation, the firm promptly identifies the latest international technological trends and seizes investment opportunities driven by technological innovation. Chende Capital is committed to discovering top-tier enterprises with the potential for industry leadership. Through an interconnected, win-win investment methodology and a precise, pragmatic post-investment empowerment system, it collaborates with entrepreneurs to build an industrial ecosystem and achieve mutual growth, thereby delivering sustainable, superior returns to investors.

Changhai Capital is a financial advisory firm specializing in the healthcare sector, providing companies with in-depth, customized financing strategies and services. The team possesses extensive industry experience in life sciences, medical devices, in vitro diagnostics (IVD), and healthcare services, having led or participated in the financing rounds of numerous high-profile enterprises. Changhai Capital assists companies in accelerating their growth and maximizing their value.